Literature DB >> 16495527

The frequency of Chlamydia trachomatis major outer membrane protein-specific CD8+ T lymphocytes in active trachoma is associated with current ocular infection.

Martin J Holland1, Nkoyo Faal, Isatou Sarr, Hassan Joof, Mass Laye, Ewen Cameron, Frederick Pemberton-Pigott, Hazel M Dockrell, Robin L Bailey, David C W Mabey.   

Abstract

Chlamydia-specific cytotoxic T lymphocytes are able to control model infections but may be implicated in disease pathogenesis. HLA-A2 peptide tetramers to Chlamydia trachomatis major outer membrane protein 258-266 (MOMP258-266) and MOMP260-268 were used to characterize HLA class I-restricted CD8+ T cells in Gambian children aged 4 to 15 years with clinical signs of active trachoma and/or infection with C. trachomatis. The frequencies of circulating HLA-A2 tetramer binding cells (TBC) were determined in whole blood samples by flow cytometric analysis. Initial screening of subjects with an anti-HLA-A2 antibody confirmed the presence of either HLA-A2 or HLA-A28. These were subsequently further divided by molecular subtyping. The C. trachomatis-specific HLA-A2 peptide tetramers were able to bind T cells with receptors from subjects which were restricted by either the HLA-A2 or the HLA-A28 restriction element. In this population, the median value of C. trachomatis-specific CD8+ T cells was 0.02%, with frequencies of up to 3.71% of CD8+ T cells reactive with a single tetramer in a minority of subjects. TBC were detected more often in subjects who were infected at the ocular surface, and their presence was associated with infection episodes of longer duration. Detection of C. trachomatis-specific TBC was not associated with the presence of disease or with the estimated load of ocular C. trachomatis infection at the time of sample collection. High frequencies of C. trachomatis-specific cells did not predict subsequent appearance or resolution of the clinical disease signs of active trachoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16495527      PMCID: PMC1418621          DOI: 10.1128/IAI.74.3.1565-1572.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules.

Authors:  J Sidney; S Southwood; D L Mann; M A Fernandez-Vina; M J Newman; A Sette
Journal:  Hum Immunol       Date:  2001-11       Impact factor: 2.850

Review 2.  Epitope clusters in the major outer membrane protein of Chlamydia trachomatis.

Authors:  S K Kim; R DeMars
Journal:  Curr Opin Immunol       Date:  2001-08       Impact factor: 7.486

3.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes.

Authors:  Edith M Janssen; Edward E Lemmens; Tom Wolfe; Urs Christen; Matthias G von Herrath; Stephen P Schoenberger
Journal:  Nature       Date:  2003-02-09       Impact factor: 49.962

4.  Failure to detect HLA-A*6802-restricted CD8+ T cells specific for Chlamydia trachomatis antigens in subjects from trachoma-endemic communities.

Authors:  O S Mahdi; H C Whittle; H Joof; D C Mabey; R L Bailey
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

5.  CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia trachomatis.

Authors:  S P Fling; R A Sutherland; L N Steele; B Hess; S E D'Orazio; J Maisonneuve; M F Lampe; P Probst; M N Starnbach
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

6.  Development of a quantitative gene expression assay for Chlamydia trachomatis identified temporal expression of sigma factors.

Authors:  S A Mathews; K M Volp; P Timms
Journal:  FEBS Lett       Date:  1999-09-24       Impact factor: 4.124

7.  Human leucocyte antigen supertypes and immune susceptibility to HIV-1, implications for vaccine design.

Authors:  K S MacDonald; L Matukas; J E Embree; K Fowke; J Kimani; N J Nagelkerke; J Oyugi; P Kiama; R Kaul; M A Luscher; S Rowland-Jones; J Ndinya-Achola; E Ngugi; J J Bwayo; F A Plummer
Journal:  Immunol Lett       Date:  2001-11-01       Impact factor: 3.685

8.  Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases.

Authors:  W Kuon; H G Holzhütter; H Appel; M Grolms; S Kollnberger; A Traeder; P Henklein; E Weiss; A Thiel; R Lauster; P Bowness; A Radbruch; P M Kloetzel; J Sieper
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

9.  CD8+ T cells specific for a potential HLA-A*0201 epitope from Chlamydophila pneumoniae are present in the PBMCs from infected patients.

Authors:  Jean-Philippe Carralot; Claudia Dumrese; Ralf Wessel; Reimer Riessen; Ingo Autenrieth; Steffen Walter; Oliver Schoor; Stefan Stevanovic; Hans-Georg Rammensee; Steve Pascolo
Journal:  Int Immunol       Date:  2005-03-31       Impact factor: 4.823

10.  Direct detection and magnetic isolation of Chlamydia trachomatis major outer membrane protein-specific CD8+ CTLs with HLA class I tetramers.

Authors:  S K Kim; L Devine; M Angevine; R DeMars; P B Kavathas
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

View more
  8 in total

1.  Enhanced Direct Major Histocompatibility Complex Class I Self-Antigen Presentation Induced by Chlamydia Infection.

Authors:  Erik D Cram; Ryan S Simmons; Amy L Palmer; William H Hildebrand; Daniel D Rockey; Brian P Dolan
Journal:  Infect Immun       Date:  2015-11-23       Impact factor: 3.441

Review 2.  Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies.

Authors:  Byron E Batteiger; Fujie Xu; Robert E Johnson; Michael L Rekart
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

3.  Helicobacter pylori HopE and HopV porins present scarce expression among clinical isolates.

Authors:  Maritza Lienlaf; Juan Pablo Morales; María Inés Díaz; Rodrigo Díaz; Elsa Bruce; Freddy Siegel; Gloria León; Paul R Harris; Alejandro Venegas
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

4.  Human leukocyte antigen (HLA)-B, DRB1, and DQB1 allotypes associated with disease and protection of trachoma endemic villagers.

Authors:  Muneer Abbas; Linda D Bobo; Yu-Hsiang Hsieh; Noureddine Berka; Georgia Dunston; George E Bonney; Victor Apprey; Thomas C Quinn; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-09-29       Impact factor: 4.799

Review 5.  Trachoma and Ocular Chlamydial Infection in the Era of Genomics.

Authors:  Tamsyn Derrick; Chrissy h Roberts; Anna R Last; Sarah E Burr; Martin J Holland
Journal:  Mediators Inflamm       Date:  2015-09-03       Impact factor: 4.711

6.  Immunofibrogenic Gene Expression Patterns in Tanzanian Children with Ocular Chlamydia trachomatis Infection, Active Trachoma and Scarring: Baseline Results of a 4-Year Longitudinal Study.

Authors:  Athumani M Ramadhani; Tamsyn Derrick; David Macleod; Patrick Massae; Tara Mtuy; David Jeffries; Chrissy H Roberts; Robin L Bailey; David C W Mabey; Martin J Holland; Matthew J Burton
Journal:  Front Cell Infect Microbiol       Date:  2017-09-15       Impact factor: 5.293

7.  Genome-wide profiling of humoral immunity and pathogen genes under selection identifies immune evasion tactics of Chlamydia trachomatis during ocular infection.

Authors:  Harry Pickering; Andy Teng; Nkoyo Faal; Hassan Joof; Pateh Makalo; Eunice Cassama; Meno Nabicassa; Anna R Last; Sarah E Burr; Sarah L Rowland-Jones; Nicholas R Thomson; Chrissy H Roberts; David C W Mabey; Robin L Bailey; Richard D Hayward; Luis M de la Maza; Martin J Holland
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

8.  The effect of infectious dose on humoral and cellular immune responses in Chlamydophila caviae primary ocular infection.

Authors:  Ana Filipovic; Ehsan Ghasemian; Aleksandra Inic-Kanada; Ivana Lukic; Elisabeth Stein; Emilija Marinkovic; Radmila Djokic; Dejana Kosanovic; Nadine Schuerer; Hadeel Chalabi; Sandra Belij-Rammerstorfer; Marijana Stojanovic; Talin Barisani-Asenbauer
Journal:  PLoS One       Date:  2017-07-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.